PharmaTimesNews & Politicsnews

EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC

Tuesday, July 14, 2026John PinchingView original

Breakwater data show significant survival gains over standard chemotherapy

Read the full article on the original site.

Read Full Article